Why BGPT?
logo

Review Papers Claim by Claim

Check each claim against its experiments, reported results, scope, and stated limitations.Know what the science actually supports before you trust the answer.

Press Enter ↡ to start review



    Explore by Goal












     Quick Explanation


    The target paper (DOI 10.3390/ijms21113749) is not present in the supplied claim-level evidence records, so a claim-accurate review of its pathway-specificity controls and effect sizes cannot be produced from the provided data. The nearest related record is the Act1/IL-17 pathway-adaptor study in psoriatic arthritis (TRAF3IP2 variants, D10N reducing TRAF6 binding, GWAS of 609 cases/990 controls replicated in 5,488 individuals), which exemplifies pathway-specific genetic effects and modest effect sizes ().


     Long Explanation


    Evidence Gap for DOI 10.3390/ijms21113749

    The supplied evidence records do not include the paper with DOI 10.3390/ijms21113749, so its specific pathway-specificity controls, effect sizes, sample sizes, and author list cannot be verified here, and fabricating a review would violate evidentiary standards.

    The closest thematically relevant record is the Act1/psoriatic arthritis study, which demonstrates a key principle of pathway specificity: a pathway-adaptor protein (Act1/TRAF3IP2) whose coding variant (D10N, rs33980500) selectively impairs TRAF6 binding while another variant (R74W, rs13190932) does not, revealing discrimination between IL-17 and alternative signaling routes .

    What is missing to complete this review: the full text, reported effect sizes (ORs/betas with confidence intervals), pathway-specificity control conditions, and author names for the requested DOI. You can fetch and analyze the paper directly with the AI Scientist agent below, or query BGPT with the DOI.



    Feedback:    

    Updated: September 30, 2026

     BGPT Paper Review


    Study Novelty

    50%

    Novelty cannot be assessed because the paper's full text is absent from the supplied evidence; the mid score reflects uncertainty, not a verified evaluation.


    Scientific Quality

    50%

    Scientific quality cannot be verified without the paper text; the score is neutral pending access. No evaluation of controls or effect sizes was possible from supplied records.


    Study Generality

    50%

    Generality unassessable from available evidence; pathway-specificity topics span many fields but the specific paper scope is unknown.


    Study Usefulness

    50%

    Practical usefulness cannot be judged without the paper's reported results; mid score reflects missing information rather than a verified assessment.


    Study Reproducibility

    50%

    Reproducibility cannot be evaluated because methods, data availability, and controls of the requested paper were not provided in the evidence records.


    Explanatory Depth

    50%

    Explanatory depth unassessable without the paper text; the neutral score reflects the evidence gap, not a critical judgment.

     Top Data Sources ExportMCP


     Hypothesis Graveyard


    That all GWAS hits at TRAF3IP2 cause disease via altered TRAF6 binding β€” falsified in the Act1 record because intronic SNPs (rs13196377, rs13210247) are associated without any demonstrated coding-effect mechanism, and R74W binds TRAF6 normally.

     Science Art


    Paper Review: 10.3390/ijms21113749 pathway specificity controls and effect sizes Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT






     Trending